Search

605 Result(s)
Sort by

Life forward

Life forward

In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Partnering pet therapeutics

Partnering pet therapeutics

Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Our people

Our people

Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation